The delisting is now irrevocable. Expect continued deterioration in liquidity and possible SEC deregistration (Form 15) which would halt public reporting. Existing OTC holders face minimal catalyst for recovery unless the company announces a business combination or reverse merger—unlikely given the sustained non-compliance.
Price Chart
Executive Summary
Nasdaq has filed a Form 25-NSE to formally remove CERO Therapeutics' securities from listing and registration, effective July 23, 2026, after the company failed to meet continued listing requirements under Rule 5550(b)(1) and exhausted all appeals through Nasdaq's hearing and review process. The company's securities have been suspended since October 31, 2025, and this filing makes the delisting final, further reducing liquidity and likely pushing the stock deeper into OTC territory.
Key Facts
- Delisting effective at the opening of trading on July 23, 2026
- Nasdaq Staff determined the company no longer met Listing Rule 5550(b)(1) (equity/market cap/income requirements)
- Securities have been suspended since October 31, 2025
- All appeals—Panel, NLHRC, and Board of Directors—were exhausted; final action letter issued February 6, 2026
- Securities include common stock and warrants
Financial Impact
Delisting from Nasdaq eliminates exchange-traded liquidity, likely triggering further price erosion and potential default covenants; no specific dollar amounts in the filing.
Risk Factors
- Further loss of liquidity as institutional holders exit OTC positions
- Risk of SEC deregistration, ending public reporting obligations
- Potential acceleration of debt or other contractual obligations tied to Nasdaq listing
- No visible operational catalyst to reverse the decline
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 25-NSE Filing (CERO) — Batch item 1 | 0001354457-26-000670 |
| Document: 0001354457-26-000670-index-headers.html | 0001354457-26-000670 |
| Document: 0001354457-26-000670-index.html | 0001354457-26-000670 |
| Document: 0001354457-26-000670.txt | 0001354457-26-000670 |
| 25-NSE Filing (CERO) — Batch item 5 | 0001354457-26-000670 |
| Document: 0001354457-26-000670-index-headers.html | 0001354457-26-000670 |
| Document: 0001354457-26-000670-index.html | 0001354457-26-000670 |
| Document: 0001354457-26-000670.txt | 0001354457-26-000670 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 31, 2026 4w ago | 8-K | $0.0120 $0.0105 | ▲ +12.50% | ▲ +13.68% | $0.0110 (+8.33%) |
Jul 13, 2026 11w ago | 25-NSE | $0.0150 $0.0100 | ▲ +33.33% | ▲ +36.52% | $0.0110 (+26.67%) |
Jun 26, 2026 14w ago | 8-K | $0.0110 $0.009700 | ▲ +11.82% | ▲ +11.56% | $0.0110 (+0.00%) |
Mar 11, 2026 29w ago | 8-K | $0.0350 $0.0340 | ▲ +2.86% | ▲ +3.38% | $0.0110 (+68.57%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access